One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Can We Find a Place for Trophoblast Cell Surface Antigen 2–Targeted Antibody-Drug Conjugates in Lung Cancer?
doi : 10.1200/JCO-24-01900
2025, Volume 43 (3)
Growing Evidence for the Role of Air Pollution in Breast Cancer Development
doi : 10.1200/JCO-24-01987
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
doi : 10.1200/JCO-24-01887
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
doi : 10.1200/JCO-24-01544
Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study
doi : 10.1200/JCO.24.00418
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
doi : 10.1200/JCO.24.00920
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
doi : 10.1200/JCO.24.00358
Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
doi : 10.1200/JCO.23.02718
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
doi : 10.1200/JCO.23.02470
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
doi : 10.1200/JCO.24.00049
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
doi : 10.1200/JCO.24.00410
Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy
doi : 10.1200/JCO-24-01619
Misleading Reporting of a Negative Randomized Clinical Trial May Affect Clinical Practice
doi : 10.1200/JCO.24.01104
UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan–Related Toxicity
doi : 10.1200/JCO-24-01366
